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The mitochondrial translocator protein (TSPO) performs a rate-limiting step in
the conversion of cholesterol to pregnenolone and its steroid derivatives. Previous
studies have shown that TSPO is upregulated in microglia and astroglia during
neural inflammation, and radiolabelled TSPO ligands such as PK11195 have been
used to image and localize injury in the CNS. Recent studies have shown that
modulating TSPO activity with pharmacological ligands such as etifoxine can
initiate the production of neurosteroids locally in the injured CNS. In this study,
we examined the effects of etifoxine, a clinically available anxiolytic drug, in the
development and progression of mouse experimental autoimmune encephalo-
myelitis (EAE), an experimental model for multiple sclerosis (MS). Our results
showed that etifoxine attenuated EAE severity when administered before the
development of clinical signs and also improved symptomatic recovery when
administered at the peak of the disease. In both cases, recovery was correlated
with diminished inflammatory pathology in the lumbar spinal cord. Modulation
of TSPO activity by etifoxine led to less peripheral immune cell infiltration of the
spinal cord, and increased oligodendroglial regeneration after inflammatory
demyelination in EAE. Our results suggest that a TSPO ligand, e.g. etifoxine,
could be a potential new therapeutic option for MS with benefits that could be
comparable to the administration of systemic steroids but potentially avoiding
the detrimental side effects of long-term direct use of steroids.INTRODUCTION
The translocator protein (TSPO), formerly known as the
peripheral benzodiazepine receptor (PBR), has been implicated
in central nervous system (CNS) injury and disease. TSPO is a
five transmembrane protein located on the outer mitochondrialedicine, School of
thaca, NY, USA
hriners Hospitals of
iversity of California,
ce, Xiangyang, Hubei,
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Ltd on behalf of EMBO. Thi
C BY 3.0), which permits u
d.membrane (Korkhov, 2010). It is found constitutively through-
out the body, but is upregulated in cells that are steroidogenic,
such as adrenal and leydig cells (Roivainen, 2009). The main
role of TSPO is the transportation of cholesterol across the outer
mitochondria membrane, the rate limiting step of steroidogen-
esis. Upregulation of TSPO is seen in many CNS diseases,
including Alzheimer’s, (Edison, 2008; Yasuno, 2008) Hunting-
ton’s, (Meßmer & Reynolds, 1998) brain tumours, (Vlodavsky &
Soustiel, 2007) traumatic brain injury, (Papadopoulos & Lecanu,
2009) ischaemic stroke, (Cosenza-Nashat, 2009; Gerhard, 2005)
frontotemporal dementia, (Cagnin, 2004) amyotrophic lateral
sclerosis, (Turner, 2004) Parkinson’s (Ouchi, 2005) and multi-
ple sclerosis (MS) (Versijpt, 2005; Vowinckel, 1997). The
prevalence of TSPO in CNS disorders has given credence to the
targeting of TSPO as a possible disease modifier. Several TSPO
ligands have been developed and used for in vivo imaging of
TSPO to illustrate areas of the affected brain in disease.s is an open access article under
se, distribution and reproduction
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892However, there is no designed TSPO ligand used as a therapeutic
agent.
Etifoxine is a clinically available drug and a TSPO ligand.
Initially designed as an anxiolytic agent, etifoxine was later
found to have a strong affinity for TSPO (Verleye, 2005).
Previous studies have shown beneficial effects of etifoxine,
including the ability to promote neuronal regeneration in the
periphery, the stimulation of neural steroidogenesis, and
anxiolytic properties (Girard, 2008; Schlichter, 2000; Ugale,
2007). Many other TSPO ligands have also shown potential CNSFigure 1. Expression of TSPO in the spinal cord of normal and EAE mice.
A. TSPO was generally expressed at low levels in the normal adult spinal cord.
B. In contrast, TSPO was markedly upregulated in EAE mice.
C. The main site of TSPO in healthy mice was the central canal ependymal cells
D. TSPO was also expressed in a small population of NG2þ cells in the normal s
E. TSPO was observed in activated astrocytes (GFAPþ) in EAE mice.
F. The majority of the cells expressing TSPO were activated microglia and infilt
G. TSPO mRNA levels also showed a dramatic increase in response to inflamma
and microglia (p¼0.01) treated with IFN-g all showed an increase in TSPO
bar¼50mm.
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.effects; they have demonstrated the ability to downregulate
microglial activation and to promote neuronal survival and
repair (Ferzaz, 2002; Ryu et al, 2005; Veiga et al, 2005).
However, no studies have been performed to determine the
direct effects of etifoxine in CNS damage and repair.
There is substantial evidence indicating that promotion of
neurosteroid synthesis may be beneficial in CNS diseases. It
has been previously reported that MS patients show a drop in
neurosteroid levels, and treatment with the neurosteroid
allopregnanolone leads to a partial rescue in mice, causing, which remained in similar high levels of TSPO expression after EAE.
tate and remained similar in the disease state.
rating macrophages (CD68þ) in EAE mice.
tory signals. EAE spinal cords (p¼ 0.004), as well as astrocytes (p¼ 0.006)
mRNA levels. The p-values were calculated by t-test, n¼ 8/group. Scale
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Daniel J. Daugherty et al.downregulation of microglial activation and infiltration of
peripheral immune cells, and protecting the myelin sheath
(Noorbakhsh, 2011). Other studies have also shown that the
neurosteroid progesterone is beneficial in the mouse model of
MS (Giatti, 2012; Yu, 2010). The increase in neurosteroid
production by etifoxine could lead to similar effects as direct
neurosteroid treatment, along with offering the direct down-
regulation of immune cell activity.Figure 2. Effect of etifoxine treatment starting at day 7 p.i. in EAE mice.
A. Etifoxine treatment was started on day 7 post induction, and was adminis
B. The drug treated group showed a decrease in clinical scoring at days 14–1
C. The drug treated group showed a significant increase in weight retention
D–G. The mice showed a significant decrease in the total scoring (p¼0.000001
(p¼ 0.03) (F), and a delayed onset of clinical scoring (p¼0.04) (G). The p-v
test, for total scores using Wilcoxon signed-rank test, and for days till ons
EMBO Mol Med (2013) 5, 891–903 To study the effects of the TSPO ligand etifoxine on
neuroinflammatory damage, we used experimental autoimmune
encephalomyelitis (EAE), a model of MS in mice in which
an autoimmune response was induced against the myelin
oligodendrocyte glycoprotein (MOG) peptide (aa 35–55). Through
administration of etifoxine at different time points, we determined
the protective and regenerative effects of the TSPO ligand
treatment on inflammatory demyelination in EAE mice.tered daily i.p. at a dose of 50mg/kg.
6.
during the peak of clinical symptoms.
) (D), an increase in the survival rate (E), a decrease in the maximal score
alues for EAE clinical scores and weight were calculated using Mann–Whitney
et and maximal score using t-test, n¼10 mice/group.
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 893
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894RESULTS
Expression of TSPO in the normal and diseased CNS
The expression level of TSPO in the normal mouse spinal cord
was very low (Fig 1A), with the exception of the ependymal cell
layer of the central canal (Fig 1C). There was only sporadic
expression of TSPO in microglia and in the cells of the
cardiovascular system. However, there was a sharp increase of
TSPO expression during EAE (Fig 1B). During the initial
progression of EAE, TSPO was prominently upregulated
in activated microglia and macrophages (Fig 1F). Later
expression was also seen in GFAPþ astrocytes (Fig 1E). A
small population of NG2þ cells (Fig 1D) also showed TSPO
expression both in normal and EAE mice. There was strong
TSPO expression in infiltrating immune cells. No expression
was seen in neurons or mature oligodendrocytes. To quantitate
TSPO expression in control and diseased animals, we preformed
mRNA analysis to show the dramatic change in TSPO
expression. TSPO expression was markedly increased in the
spinal cords of EAE mice (Fig 1G), as well as in response to
inflammatory cytokine stimulation in both microglia and
astrocytes (Fig 1G).
Prophylactic effect of etifoxine on EAE in mice with the drug
treatment starting on day 7 post MOG injection
EAE was induced with subcutaneous flank injections of the
MOG peptide (aa 35–55) in complete Freund’s adjuvant (CFA)
followed by intraperitoneal administration of pertussis toxin on
days 0 and 2 in 10-week-old C57BL/6 mice (Fig 2A). Etifoxine
(50mg/kg) or vehicle (1% Tween-80, control) was adminis-
tered daily at defined time periods during the course of EAE
(Fig 2A). Neurological deficits were evaluated and graded on a
five-point scale for 40 days. Animals in the etifoxine treated
group showed a decrease in the peak of clinical scores of EAE
(Fig 2B), as well as delayed onset of the first signs of clinical
symptoms (Fig 2D–G). The control group peaked at a median
score of 3 on day 14, compared to the drug treated group with a
peak median score of 1.5 on day 17. This 50% decrease in
median score peak as well as the 3-day delay of onset indicates a
prophylactic effect of etifoxine. In EAE, clinical scores are
directly related to the amount of damage caused by inflamma-
tory damage. In addition to showing lower clinical scores, the
drug treated group had increased animal survival (Fig 2E).
There were no deaths recorded in the drug treated group with
100% surviving the trial, while only 80% of mice in the control
group survived. The change in the mean body weight also
reflected that of the clinical scores. Muscle wasting due to CNS
damage is a reliable indicator of EAE progression. Mean bodyFigure 3. Histological and mRNA analysis of the inflammatory cytokines in th
A–D. At day 10 p.i., drug treated animals showed significant differences in MBP (
showed an increase in retention of percentage of MBP coverage (p¼ 0.001
(p¼ 0.004) (B), along with less Iba1þ cells per mm2 (p¼0.02) (C). (D) The ve
the drug treated group. Infiltrated CD4þ cells were positive for TSPO expre
E. The mRNA levels corroborated the CD4 histology. Along with the decrease in
cytokines interferon-g (IFN-g) (p¼0.02) and interleukin 17 (IL-17) (p¼ 0.
n¼8/group.
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.weight loss during the peak of the disease was significantly less
in mice treated with etifoxine than in mice in the control group.
Control mice had mean weight bottom out at 17 g at day 15,
while the drug treated group had a mean weight of 19.5 g at
day 15. There was a 35% decrease in total clinical scores.
The etifoxine treated group showed a delay in onset (Fig 2G),
as well as a lessened severity at the peak of EAE.
Immune response of mice at the onset of clinical signs
during EAE and the effect of the prophylactic treatment
with etifoxine
At the initial onset of EAE clinical symptoms, there was a sharp
increase in TSPO expression (Fig 3A–C). Treatment with
etifoxine delayed this increase. The vehicle group had an
average of 500 TSPOþ cells per square mm, while the etifoxine
treated group had 122. A similar effect was seen in the
Iba1þ microglial cell population (Fig 3C). The control group
averaged 717 Iba1þ cells per square mm compared to the drug
treated group 153. This finding is not surprising as TSPO is
known to upregulate in activated microglia. The increased
TSPOþ cells were mostly activated microglia in response to
injury. The fourfold increase in TSPOþ and Iba1þ cells indicates
that treatment with etifoxine causes a decrease in microglial
activation through modulation of TSPO.
The decrease in microglia activation was also correlated with
the retention of myelin basic protein (MBP) expression (Fig 3A).
The control group had a MBPþ % surface area of 40%, while
the etifoxine treated group had a total MBP surface area of 58%.
The preservation of the myelin sheath indicates that etifoxine
treatment lessens the immune response against oligodendro-
cytes and protects the myelin.
In addition, infiltration of CD4þ cells was present in the
vehicle treated group, but no CD4þ cells were seen in
the etifoxine treated group (Fig 3D). CD4þ cells also stained
positive for TSPO. The mRNA analysis confirmed the decrease
in CD4 expression in the lumbar section of EAE spinal cords.
There was also a decrease in interferon-g and interleukin-17
mRNA expression, two prominent cytokines produced by
CD4þ cells (Fig 3E).
Effect of a delayed etifoxine regimen on EAE in mice with the
drug treatment starting on day 18 post MOG injection
When etifoxine administration began at the peak of the EAE
clinical symptoms (Day 18) (Fig 4), mice treated with the drug
had improved recovery from the clinical symptoms compared
to the control group. After peaking at a median score of 4 on
day 18, the drug group dropped to a median score of 1.75 by
day 36. The control group median clinical score never droppede vehicle- or etifoxine-treated mice at onset of clinical symptoms.
A), TSPO (B), Iba1 (C) and CD4 staining (D). (A) Animals treated with etifoxine
). Etifoxine treated animals also exhibited a decrease in TSPOþ cells per mm2
hicle group showed infiltration of CD4þ cells, while no CD4þ cells were seen in
ssion.
CD4 mRNA (p¼ 0.01), there was a decrease in transcripts of the inflammatory
04) in animals treated with etifoxine. The p-values were calculated by t-test,
"
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Figure 3.
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Figure 4. Effect of etifoxine treatment starting at day 18 p.i. in EAE mice.
A–C. Treatment of etifoxine was started at the peak of EAE (day 18), and continued daily at a dose of 50mg/kg i.p. (A) The drug treated group showed a decrease in
clinical scores (B), with an increase in weight gain (C).
D–G. The etifoxine group also showed a decrease in the total scoring (D), greater animal survival (E), a decrease in the mean low score (p¼0.01) (F), and a
decrease in days of paralysis after treatment (p¼0.004) (G). The p-values for EAE clinical scores and weight were calculated using Mann–Whitney test, for
total scores using Wilcoxon signed-rank test, and for the mean low score and days of paralysis after treatment using t-test, n¼ 12 mice/group.
896below 3, after peaking at 4 on day 18. While recovery after
the peak of the disease is common in EAE trials, etifoxine did
induce an increased recovery rate compared to the control. As
with the drug administration on day 7, the clinical scores
correlated with the mean weights of the cohorts. The etifoxine
group regained 2 g of lost weight from 17 to 19 g. The control
group showed less weight recovery at only 1 g, increasing from
16 to 17 g. The etifoxine treated group also showed increased
survival and a decrease in the total scoring, in the mean low
score, and in days of paralysis.
We also performed histological analysis of these vehicle- or
etifoxine-treated mice at the recovery phase of EAE (Fig 5).
The drug treated group retained more MBPþ total percentage
area than the vehicle control, along with less Iba1þ cells and less
infiltrating CD4þ cells.
Immune response of mice at the onset of clinical signs during
EAE and the effect of etifoxine treatment
A major contributor of the EAE clinical symptoms is the
infiltration of peripheral immune cells into the CNS. T-cell
infiltrates were measured by CD4 staining. At day 15, post-MOG
injection, the control group developed more infiltration of CD4þ
cells (Fig 6A). This was correlated with a protection of MBP%
coverage, and a lessened population of Iba1þ cells. CD4þ cell
infiltration was also measured through flow cytometry analysis.
Etifoxine-treated mice showed a decrease in the percentage of 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.CD4þ cells as well as CD8þ cells, which coincided with a
decrease in CD4þ/IL-17þ cells as well as CD8þ/IFN-gþ cells
(Fig 6B).
We also measured the protein levels of the inflammatory
cytokines by ELISA analysis, and showed a decrease in
interleukin-1b, interleukin-17 and interferon-g protein levels
in the spinal cords of EAE mice treated with etifoxine (Fig 6C).
Effect of the delayed treatment of etifoxine on NG2
expression, remyelination and 3a-hydroxysteroid
dehydrogenase during the recovery phase of the EAE
We next examined whether etifoxine might promote a
regenerative response after demyelination in EAE mice. The
etifoxine treated group showed an increase in NG2þ cells (Fig 7).
This increase was seen mostly in the dorsal area proximal to the
central canal, and around injury plaques. It was observed that
the NG2þ cells had a trail of migration from the dorsal central
canal toward the sites of injury. The central canal NG2þ cells
were co-labelled with TSPO. The mRNA analysis showed an
increase in expression of the oligodendroglial markers proteo-
lipid protein (Plp) and Olig2 in the drug treated group. An
increase in myelination was also demonstrated by the EM
analysis (Fig 8). Drug-treated animals demonstrated an increase
in the extent of myelinated axons. In addition, mRNA levels of
the main 3a-hydroxysteroid dehydrogenase (3aHSD) ark1c14
that is responsible for the production of the neurosteroidEMBO Mol Med (2013) 5, 891–903
www.embomolmed.org Research Article
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Figure 5. Histological analysis of the vehicle- or etifoxine-treated mice at the recovery phase of EAE. At the peak of EAE clinical symptoms, the drug treated
group retained more MBPþ total percentage area than the control (p¼ 0.02), along with less Iba1þ cells per mm2 (p¼ 0.004) and less infiltrating CD4þ cells per
mm2 (p¼0.03). The p-values were calculated using t-test, n¼8/group.allopregnanolone were upregulated 50% in animals receiving
drug treatment (Fig 7C).DISCUSSION
While there is currently no cure for MS, there are multiple forms
of therapy. The administration of oestrogen and testosterone has
been shown to have a beneficial effect in ameliorating the
symptoms of MSwhile progesterone and allopregnanolone have
been effective in EAE (Gold, 2008; Noorbakhsh, 2011; Soldan,
2003; Yates, 2010). However, long-term steroid treatment has
detrimental side effects, and may not be ideal as a viable option
for people suffering from MS. The search for a drug with the
same efficacy, yet safer than steroids has been a goal in MS
research. Our data presented here indicate that the use of
TSPO ligands may be a viable drug candidate for neuroin-
flammatory treatment. Non-benzodiazepines, such as etifoxine,EMBO Mol Med (2013) 5, 891–903 are relatively safe for long-term use, and are known to increase
endogenous neurosteroid levels (Verleye, 2005).
The administration of etifoxine, through its promotion of
steroidogenesis, may lead to the inhibition of infiltration of
peripheral immune cells during the course of EAE. The initial
onset of EAE symptoms was delayed when mice were
administered etifoxine before the onset of clinical signs. The
onset of clinical symptoms in EAE is initiated by the infiltration
of peripheral antigen presenting cells and invasive T cells.
Previous studies have shown that TSPO ligands could modulate
macrophage activity, including affecting oxidative burst and
the release of inflammatory cytokines (Ruff, 1985; Choi, 2002).
Our results showed that there was a decrease in activation
of Iba1þ cells. There was also a sharp decrease in CD4þ cells.
CD4þ T cells are one of the main infiltrating immune cells
during EAE. It was also demonstrated that this decrease in
infiltration of CD4þ and CD8þ cells was accompanied by a
decrease in inflammatory active T cells. There was a decrease in2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 897
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Figure 6. Etifoxine modulation of T-cell activity during EAE. Spinal cords of vehicle- or etifoxine-treated mice were either used for flow cytometry analysis or
ELISA analysis. Cells stained for CD4, CD8, IL-17 and IFN-g were gated according to fluorescent intensity.
A. Cells were then measured as a percentage of the total cell population. There was a decrease in the percentage of CD4þ (p¼0.04), CD4þ/IL-17þ (p¼0.04),
CD8þ (p¼ 0.01) and CD8þ/IFNgþ (p¼ 0.03) cells in the drug-treated group
B. Protein levels of the inflammatory cytokines IL-1b (p¼ 0.001), IL-17 (p¼0.02) and IFN-g (p¼ 0.02) were also measured, and there was a significant
decrease in all cytokines in response to etifoxine treatment
C. The p-values were calculated using t-test, n¼8/group.
898IL-17þ/CD4þ T cells with drug treatment. Previous studies have
shown that Th17 T cells play a crucial role in advancement of
EAE, and IL-1b is an important modulator of Th17 cell
development (El-Behi et al, 2011). The drug-treated group not
only showed a decrease in CD4þ cells and CD4 mRNA
expression, but also a decrease in pro-inflammatory cytokines
interferon-g and interleukin-17 mRNA levels, along with
decreased protein levels of interferon-g, interleukin-17 and
interleukin-1b.
The modulation of TSPO also showed beneficial effects after
neural injury. After the peak of clinical signs in EAE, it is
common to see a recovery of limb function and lower clinical
scores in EAE mice. When etifoxine was administered at day 18,
the peak of the disease, mice showed improved recovery, and
retained the recovery over the course of the experiment. This
was seen in both body weight and clinical scoring. Etifoxine
promoted the retention of MBP, and the inhibition of microglia
and CD4þ cells. A major target of the inflammatory damage to
the CNS in EAE and MS is the oligodendrocyte, damaging the
myelination of axons in the spinal cord. Previous studies have 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.shown that, during EAE, there is a proliferative response of
NG2þ cells in the spinal cord in response to injury (Tripathi,
2010). We found a greater increase in NG2þ cells in the
spinal cord of the etifoxine treated mice than that of the control
(Fig 6).
The increased expression of TSPO and NG2 was most
prominent around the central canal of the spinal cord. This is not
surprising, as other studies have shown that the ependymal
layer of the central canal is a possible location of regenerative
response (Hamilton, 2009). In many instances, an upregulation
of TSPOwas seen in the ependymal layer. TSPO has been shown
to play a role in cell proliferation and differentiation (Varga,
2009). Neurosteroids have been shown to increase oligoden-
droglial cell numbers and MBP expression(Ghoumari, 2003;
Ghoumari et al, 2005), suggesting that TSPO ligands could aid in
oligodendroglial regeneration and myelin repair in the spinal
cord. We found that mice in the drug treated group showed an
increased expression of myelin markers and an increase in NG2
and Olig2 cells, suggesting that etifoxine promotes oligoden-
droglial regeneration during the recovery phase of EAE. MiceEMBO Mol Med (2013) 5, 891–903
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Figure 7. Effect of etifoxine treatment on NG2R cells in the spinal cord during the recovery phase of EAE.
A. There was a significant increase in the NG2þ cell population in the etifoxine treated group (p¼ 0.01) compared to the vehicle treated group, and there was
also an increase in Olig2þ cells.
B. NG2þ cells were found on the dorsal side of the central canal, and extended toward sites of injury, and co-labelled with TSPO.
C. The mRNA levels of Plp (p¼0.007) and Olig2 (p¼0.02) were increased in the drug treated group, so were the levels of akr1c1 (p¼0.03), the main
3a-hydroxysteroid dehydrogenase (3aHSD) that is responsible for the biosynthesis of the neurosteroid allopregnanolone. The p-values were calculated using
t-test, n¼8/group. Scale bar¼50mm.treated with etifoxine also showed an increase in MBP
expression and the myelination of axons, as demonstrated by
EM analysis.
Previous studies demonstrated that the neurosteroid levels of
people with MS are greatly affected (Gold, 2008; Noorbakhsh,
2011; Soldan, 2003; Yates, 2010). The enzyme responsible for
the generation of allopregnanolone, 3aHSDIII, is decreased in
MS and EAE, and treatment of allopregnanolone is protective
against EAE (Gold, 2008; Noorbakhsh, 2011; Soldan, 2003;
Yates, 2010). The main 3aHSDIII isoform in mice is akr1c14
(Gold, 2008; Noorbakhsh, 2011; Soldan, 2003; Yates, 2010). In
our study, we found an increase in ark1c14mRNA levels in mice
treated with etifoxine during EAE. Our data are in accordance
with previous studies demonstrating that the anxiolytic effect of
etifoxine is mediated through allopregnanolone, and that
etifoxine increases allopregnanolone levels in the brain, through
a non-adrenal or gonadal source (Verleye, 2005). Our results
suggest a possible mechanism for the protective effect of
etifoxine treatment in EAE: Etifoxine binds TSPO and causes an
increase in cholesterol transport into the mitochondria, leading
to an increase in the production of neurosteroids, such as
allopregnanolone, which has been shown to increase oligoden-
drocyte proliferation and function, as well as to decrease the
production of pro-inflammatory cytokines.EMBO Mol Med (2013) 5, 891–903 In conclusion, our results show that the TSPO ligand
etifoxine is protective and promotes recovery in amousemodel
of MS. Our study demonstrates that through the modulation of
TSPO activity there is less peripheral immune cell infiltration
of the spinal cord, as well as increased oligodendroglial
regeneration. TSPO ligands, especially the clinically already
available etifoxine, could have new clinical applications in
the treatment of MS. Steroid administration has already
been implicated as an option for treatment. Through the
promotion of local steroid production, the use of clinically
available TSPO ligands may be a more efficacious and safer
form of treatment.MATERIALS AND METHODS
Animals
Experiments were carried out in accordance with the National
Institutes of Health guidelines for the use of laboratory animals; all
animal protocols were approved by the University of California Davis
Institutional Animal Care and Use Committee. C57BL/6 female mice
(20–25 g) were used and they were obtained from the Jackson
Laboratories (Sacramento, CA). All efforts were made to minimize the
numbers of animals used and to ensure minimal suffering.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 899
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Figure 8. Electron microscopy of the lumbar section of the spinal cord in EAE mice after vehicle or etifoxine treatment.
A. Lowmagnification electron micrograph showed a large number of degenerating myelinated axons (dAx) andmicroglia/macrophage cells (M) in the spinal cord
white matter of the vehicle-treated EAE mice. Note that the degenerating axons displayed various morphological features, but they all showed disorganized
myelin sheaths and electron-dense or swollen axoplasm. Microglia/macrophage cells (M) were frequently found to surround or be close to the degenerating
axons. Scale bar¼5mm.
B. High magnification electron micrograph taken from the same section in panel A, demonstrating that several microglia cells surrounding a degenerating axon
(dAx) where the myelin sheath completely collapsed and the axoplasm became transparent, and indicating few organelles existed at this advanced stage of
degeneration. Another degenerating axon (dAx) was seen near the microglia/macrophage (M). Scale bar¼1mm.
C. Lowmagnification electron micrograph showing the spinal cord white matter of etifoxine-treated mice after EAE. Most of the axons (Ax) were myelinated and
axonal organelles such as mitochrondria were present. No microglia or macrophages were found associating with myelinated axons. Scale bar¼5mm.
D. High magnification electron micrograph showing myelinated axons (Ax), while mitochrondria appearing normal and neurofilaments being well preserved in
the axoplasm. Inset showing higher magnification image of a myelinated axon (asterisk), with myelin sheath layers being clearly identified, and the major
dense lines and the intraperiod lines also being clearly seen. Scale bar in D¼ 1mm and in the inset¼ 0.1mm.
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The paper explained
PROBLEM:
MS is a common autoimmune demyelinating disease in humans,
and experimental allergic (autoimmune) EAE induced in mice by
immunization of animals with myelin antigens is the most
thoroughly studied experimental model of MS. Immunomodu-
latory therapies available today for MS patients decrease the
frequency of new plaques in relapsing/remitting MS, but are not
satisfactory for primary and secondary progressiveMS.Molecular
studies of neuroprotective strategies and pathologic investiga-
tions into the inflammatory response in clinically relevant
experimental models of MS will elucidate new aspects of MS
pathology and open up novel possibilities for MS therapy. The
mitochondrial TSPO has been reported to confer neuroprotection
in CNS inflammatory diseases. In this study, we seek to determine
the specific role of TSPO in EAE and to provide insights into
therapeutic strategies to block inflammation and demyelination
and promote oligodendroglial regeneration/remyelination in MS.
RESULTS:
In this study, we report the novel neuroprotective and anti-
inflammatory effect of etifoxine, a clinically available drug
that is a mitochondrial TSPO ligand, against autoimmune
demyelination in an experimental model of MS. Our study is
the first report to show that mitochondrial TSPO represents
a potential therapeutic target for MS and that the TSPO
ligand etifoxine attenuates EAE by inhibiting neural inflam-
mation, suppressing infiltration of immune cells into the
CNS, reducing demyelination and promoting oligodendroglial
regeneration. These exciting findings provide useful
information leading to a new, inexpensive strategy for treating
MS.
IMPACT:
Our results represent a novel paradigm for the
understanding of how a mitochondrial protein is critically
involved in inflammatory demyelinating lesions, which
opens a new avenue to identify a novel and specific target
for such diseases as MS. We believe that our findings
reported in this manuscript will be of great interest to a
broad readership from neuroscientists to immunologists
and to MS clinicians.Immunohistochemistry
Mice were anaesthetized and tissue fixed by transcardial perfusion.
The lumbar section of the spinal cord was isolated and placed in 4%
PFA overnight. The tissue was then cryoprotected in 30% sucrose and
frozen in OCT (Sakura Finetek, Torrance, CA). The tissue was cut into
20mm sections and kept in PBS at 48C until stained.
For immunostaining, sections were post-fixed in 4% PFA for 30mins
and washed with PBS. Non-specific binding was blocked using 5%
goat serum, and cells were perforated with 0.5% triton-X in PBS.
Antibodies for CD4 (BD Biosciences), MBP (Novus Biologicals), TSPO
(Epitomics, Iba1 (Wako), Olig2 (R&D Systems, CD68 (AbD Serotec),
GFAP (Sigma–Aldrich) and NG2 (Millipore) were incubated overnight.
The tissue was washed in PBS and counterstained with a secondary
antibody conjugated to Alexa Fluor 488 or 555 for 2 h. Nuclear
staining was done with DAPI Fluoromount G (SouthernBiotech).
Images were taken on a Nikon Eclipse TE 2000-E microscope using a
D-Eclipse C1si camera (Nikon Instruments Inc., Melville, NY). Cell
counts and MBP quantification were analysed using Image J software.
Induction of EAE and drug treatment
EAE was induced in 10-week-old mice by injecting an emulsion of
300mg of MOG peptide in CFA subcutaneously on either hind flank as
two injections. In addition, 250ng of pertussis toxin was injected
intraperitoneally on the same day as MOG–CFA, and another dose was
administered after 48 h. Body weights of mice were recorded before
MOG–CFA injection and then continuously at 2-day intervals. Disease
development was monitored daily, and the severity of clinical signs
was scored based on a standard neurological scoring system for EAE as
follows: 1, limp tail or waddling gait; 2, limp tail and ataxia; 2.5, singleEMBO Mol Med (2013) 5, 891–903 limb paresis and ataxia; 3, double limb paresis; 3.5, single limb
paralysis and paresis of second limb; 4, full paralysis of two limbs; 4.5,
moribund; and 5, dead. Scoring was performed in a blinded fashion.
Etifoxine was dissolved in 1% Tween-80 in saline solution. Vehicle was
1% Tween-80 dissolved in saline solution. Administration of etifoxine
at 50mg/kg i.p. was performed every day, starting at day 7 for the
prophylactic study, and at day 18 for the regenerative study. Body
weight was taken every other day.
Primary cell culture
P0 pups were sacrificed and hippocampal regions were isolated. Cells
were shaken for 3 h to remove microglia. The remaining cells were
incubated for 21 days, and shaken again to remove oligodendryocytes,
leaving behind astrocytes. Cells were plated and either treated with
vehicle or interferon-g. Cells were then collected and RNA was
extracted for analysis.
RNA isolation and qPCR
Mice were anaesthetized with ketamine:xylazine (100:10mg/kg) and
perfused through the heart with a phosphate-buffered saline (PBS).
Lumbar spinal cords were carefully excised and stored separately in
liquid nitrogen. Total RNA was isolated from spinal cord tissue using
RNeasy Lipid Tissue Mini Kit (Qiagen) following the standard protocol.
For quality control, RNA purity was verified using the OD260/280 ratio
to be between 1.8 and 2.0. Total RNA (1mg) was reverse-transcribed to
cDNA using MultiscribeTM reverse transcriptase (Applied Biosystems).
qPCR for GAPDH (Mm99999916_s1), CD4 (Mm00442754_m1),
INF-g (Mm01168134_m1), IL-17 (Mm00439619_m1), PLP
(Mm01297210_m1), Olig2 (Mm01210556_m1) and akr1c142013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 901
Research Article www.embomolmed.org
Etifoxine and multiple sclerosis
902(Mm00506338_m1) was performed in triplicate using the TaqMan
gene expression assay (Applied Biosystems) using a Roche Lightcycler
480. All samples were analysed and normalized with the expression
level of GAPDH, and quantification of fold-change was performed
utilizing the 2DDCt method.
Flow cytometry analysis of mononuclear cells
Mouse brains and spinal cords were isolated, homogenized in RPMI
medium containing 0.5 units/ml Wu¨nsch Liberase RI (Roche Applied
Science) and 14 g/ml DNase I (Roche Applied Science) and passed
through a 100-ml cell filter. Cells were spun down and resuspended in
40% Percoll-Plus over an underlayer of 70% Percoll-Plus. Cells were
then isolated through density gradient, and cells at the interface were
isolated. Cells were counted and plated at 5106 in 96-on-a-96-well
plates. Cells used to examine macrophage populations were im-
mediately stained. Cells used to examine T cell concentrations were
incubated 20h in RPMI medium with MOG at a final concentration of
50mg/ml. Golgi stop was added for the last 4 h of incubation. Cells
were incubated with Fc block for 20min, then washed and incubated
with the appropriate cell surface markers. Macrophages were
stained with markers for CD11b and CD45, while T Cells cultures
were stained with markers for CD4 and CD8 for 30min. Cells were
then fixed and permeabilzed. Macrophages were immediately
processed through flow cytometry. T cells were stained for internal
cytokine markers Il-17 and interferon g. Flow cytometry was done
on a CyAN flow cytometer (Dako Cytomation, Carpinteria), and all
reagents and antibodies were purchased from BD Biosciences unless
otherwise noted.
ELISA analysis of inflammatory cytokines
Mouse spinal cords were extracted and weighed. Spinal cords were
then homogenized in PBS containing protease inhibitors using
sonication. Homogenates were centrifuged (11 000 rpm for 20min
at 48C), and supernatant was extracted. Protein concentrations were
determined by BCA assay (Thermo Scientific), and samples were
diluted with sterile PBS. Samples were then analysed using ELISA kits
for Il-1b, Il-17 and IFNg (R&D Systems). Plates were read on a plate
reader at 540 nm with correction at 450nm (Molecular Devices).
Electron microscopic analysis of axons in the spinal cords of
vehcle- and drug-treated EAE mice
EAE was induced in mice and treatment with either vehicle or
etifoxine was started at the peak of disease. Mice were sacrificed on
day 25 p.i. Mice were perfused through heart with saline followed by
4% paraformaldehyde plus 2.5% glutaraldehyde in 0.1M phosphate
buffer (pH7.4) on day 25 p.i. Spinal cords containing thoracic and
lumbar segments were removed and postfixed for 2 days at 48C.
Sections were cut with a vibratome (Leica) at 70mm and collected in
cold 0.1M phosphate buffer and placed in 2% OsO4 in 0.1M
phosphate buffer for 30min, dehydrated and flat-embedded in
Araldite (Shen et al, 2012). Selected regions of the spinal cord were
dissected under a dissecting microscope and glued to the blocks.
Ultrathin sections at 70–80nm were cut on an ultramicrotome (Leica)
and serial sections were collected to single-slot Formva-coated grids.
Ultrathin sections were examined in a Philips CM120 Electron
Microscope at 80 kV. Regions containing white matter were first
imaged at 4800, and some regions were examined and imaged at 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.higher magnifications at 11000 or 20000 Digital images were
acquired by a high resolution CCD camera (2k2k) (Gatan, Inc,
Pleasanton, CA) and processed using DigitalMicrograph (Gatan).
Images were imported to Adobe Photoshop for composing figures.
Data analysis
All data represent the mean SEM. Each experimental group had at
least eight mice. All assays were performed in triplicate. Statistical
differences were assessed by analysis of variance (ANOVA) with Tukey
post hoc analysis for multiple comparisons. Student’s t-test was used
when only two independent groups were compared. For data not
satisfying assumptions of normality and homogeneity of variance, a
nonparametric Mann–Whitney test was used. p-values of <0.05 were
considered significant.Author contributions
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